S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Sell every Stock except ONE (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
Sell every Stock except ONE (Ad)
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Wall Street slips as weak earnings hit tech, travel stocks
Insiders Say New “Parallel Economy” Is Wave Of Future (Ad)pixel
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Sell every Stock except ONE (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
Sell every Stock except ONE (Ad)
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Wall Street slips as weak earnings hit tech, travel stocks
Insiders Say New “Parallel Economy” Is Wave Of Future (Ad)pixel
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Sell every Stock except ONE (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
Sell every Stock except ONE (Ad)
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Wall Street slips as weak earnings hit tech, travel stocks
Insiders Say New “Parallel Economy” Is Wave Of Future (Ad)pixel
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Sell every Stock except ONE (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
Sell every Stock except ONE (Ad)
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Wall Street slips as weak earnings hit tech, travel stocks
Insiders Say New “Parallel Economy” Is Wave Of Future (Ad)pixel
NYSE:GMED

Globus Medical - GMED Stock Forecast, Price & News

$63.79
+0.27 (+0.43%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$63.25
$64.03
50-Day Range
$53.08
$66.59
52-Week Range
$52.60
$84.23
Volume
741,489 shs
Average Volume
708,700 shs
Market Capitalization
$6.49 billion
P/E Ratio
42.81
Dividend Yield
N/A
Price Target
$77.36

Globus Medical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
21.3% Upside
$77.36 Price Target
Short Interest
Bearish
6.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
0.27mentions of Globus Medical in the last 14 days
Based on 17 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
14.76%
From $2.10 to $2.41 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

382nd out of 1,098 stocks

Surgical & Medical Instruments Industry

40th out of 112 stocks

GMED stock logo

About Globus Medical (NYSE:GMED) Stock

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Analysts Set New Price Targets

GMED has been the topic of several recent research reports. BTIG Research reduced their price target on Globus Medical to $71.00 in a research note on Tuesday. Wells Fargo & Company reduced their price target on Globus Medical from $80.00 to $70.00 in a research note on Wednesday, May 11th. Truist Financial reduced their price target on Globus Medical from $76.00 to $71.00 and set a "buy" rating on the stock in a research note on Wednesday, July 20th. Piper Sandler reduced their price target on Globus Medical from $80.00 to $75.00 and set an "overweight" rating on the stock in a research note on Friday. Finally, Canaccord Genuity Group reduced their price target on Globus Medical from $80.00 to $75.00 in a research note on Wednesday, May 11th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Globus Medical has an average rating of "Moderate Buy" and an average price target of $77.36.

Globus Medical Stock Up 0.4 %

Shares of NYSE:GMED traded up $0.27 during trading on Tuesday, reaching $63.79. The company had a trading volume of 741,489 shares, compared to its average volume of 708,700. Globus Medical has a 12-month low of $52.60 and a 12-month high of $84.23. The stock has a market cap of $6.49 billion, a PE ratio of 42.65, a P/E/G ratio of 3.01 and a beta of 1.13. The business's 50-day moving average is $58.49 and its 200 day moving average is $65.38.

Globus Medical (NYSE:GMED - Get Rating) last released its quarterly earnings data on Tuesday, May 10th. The medical device company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.46 by ($0.04). Globus Medical had a net margin of 15.91% and a return on equity of 11.81%. The business had revenue of $230.55 million for the quarter, compared to analysts' expectations of $232.88 million. During the same period last year, the business earned $0.49 earnings per share. The company's quarterly revenue was up 1.4% on a year-over-year basis. On average, analysts anticipate that Globus Medical will post 2.1 earnings per share for the current year.

Receive GMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter.

GMED Stock News Headlines

US Dollar Replaced By "Biden Bucks"?
A former advisor to the CIA and Pentagon now believes President Biden plans to retire the US dollar we know. And replace it with what he calls 'Biden Bucks'. It is underway.
Analyst Ratings for Globus Medical
Globus Medical (GMED) Q2 2022 Earnings Call Transcript
Globus Medical Reports Second Quarter 2022 Results
US Dollar Replaced By "Biden Bucks"?
A former advisor to the CIA and Pentagon now believes President Biden plans to retire the US dollar we know. And replace it with what he calls 'Biden Bucks'. It is underway.
What 5 Analyst Ratings Have To Say About Globus Medical
Globus Medical Inc Class A - Stock Quote GMED
What 6 Analyst Ratings Have To Say About Globus Medical
See More Headlines
Receive GMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter.

GMED Company Calendar

Last Earnings
11/04/2021
Today
8/09/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
37957720
Employees
2,400
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$77.36
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$62.00
Forecasted Upside/Downside
+21.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$149.19 million
Pretax Margin
19.89%

Debt

Sales & Book Value

Annual Sales
$958.10 million
Cash Flow
$2.84 per share
Book Value
$17.15 per share

Miscellaneous

Free Float
76,914,000
Market Cap
$6.49 billion
Optionable
Optionable
Beta
1.13

Key Executives














GMED Stock - Frequently Asked Questions

Should I buy or sell Globus Medical stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GMED shares.
View GMED analyst ratings
or view top-rated stocks.

What is Globus Medical's stock price forecast for 2022?

9 analysts have issued 12-month target prices for Globus Medical's stock. Their GMED share price forecasts range from $62.00 to $100.00. On average, they anticipate the company's share price to reach $77.36 in the next twelve months. This suggests a possible upside of 21.3% from the stock's current price.
View analysts price targets for GMED
or view top-rated stocks among Wall Street analysts.

How has Globus Medical's stock performed in 2022?

Globus Medical's stock was trading at $72.20 at the beginning of the year. Since then, GMED shares have decreased by 11.6% and is now trading at $63.79.
View the best growth stocks for 2022 here
.

When is Globus Medical's next earnings date?

Globus Medical is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our GMED earnings forecast
.

How were Globus Medical's earnings last quarter?

Globus Medical, Inc. (NYSE:GMED) posted its quarterly earnings results on Thursday, November, 4th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.05. The medical device company had revenue of $229.72 million for the quarter, compared to analyst estimates of $228.28 million. Globus Medical had a net margin of 15.91% and a trailing twelve-month return on equity of 11.81%. The company's revenue for the quarter was up 6.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.49 EPS.

What guidance has Globus Medical issued on next quarter's earnings?

Globus Medical updated its FY22 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of $2.10 for the period, compared to the consensus earnings per share estimate of $2.10. The company issued revenue guidance of $1.025 billion, compared to the consensus revenue estimate of $1.02 billion.

What is David Demski's approval rating as Globus Medical's CEO?

47 employees have rated Globus Medical Chief Executive Officer David Demski on Glassdoor.com. David Demski has an approval rating of 61% among the company's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Block (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA).

What is Globus Medical's stock symbol?

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

Who are Globus Medical's major shareholders?

Globus Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Geneva Capital Management LLC (1.33%), Van Berkom & Associates Inc. (0.87%), Paradigm Capital Management Inc. NY (0.68%), Boston Trust Walden Corp (0.63%), Pembroke Management LTD (0.59%) and Loomis Sayles & Co. L P (0.50%). Insiders that own company stock include Daniel T Scavilla, Daniel T Scavilla, David D Davidar, David M Demski, James R Tobin, James R Tobin, Keith W Pfeil, Keith W Pfeil, Kelly Huller and Robert Andrew Douglas.
View institutional ownership trends
.

How do I buy shares of Globus Medical?

Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Globus Medical's stock price today?

One share of GMED stock can currently be purchased for approximately $63.79.

How much money does Globus Medical make?

Globus Medical (NYSE:GMED) has a market capitalization of $6.49 billion and generates $958.10 million in revenue each year. The medical device company earns $149.19 million in net income (profit) each year or $1.49 on an earnings per share basis.

How many employees does Globus Medical have?

Globus Medical employs 2,400 workers across the globe.

How can I contact Globus Medical?

Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The official website for the company is www.globusmedical.com. The medical device company can be reached via phone at (610) 930-1800, via email at investors@globusmedical.com, or via fax at 610-930-2042.

This page (NYSE:GMED) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.